Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 2(4)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05456425Phase 3Active Not Recruiting

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Role: lead

NCT04884256Phase 2Completed

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula

Role: lead

NCT05261386Phase 2Completed

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

Role: lead

NCT04884243Phase 2Completed

Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

Role: lead

NCT05372991Phase 1Completed

Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop

Role: lead

NCT03049852Phase 2Completed

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

Role: lead

All 6 trials loaded